Reference

Singh, A., Haq, N., Yang, M., Luckey, S., Mansouri, S., Campbell-Thompson, M., Jin, L., Christou-Savina, S., & Lartigue, G. de. (2025). Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl Syndrome mouse model. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI184636


Blue: Important conclusions

Highlight ( Page 44)

Glucagon-like peptide-1R agonist (Semaglutide) promotes hypophagia3 induced weight loss and improves nesting behavior and glucose tolerance in 4 adult Bbs5 null mice.

Yellow: Interesting

Highlight ( Page 2)

iliopathy characterized by obesity, hyperphagia, and 3 learning deficits, arises from mutations in Bbs genes

Highlight ( Page 2)

BBSome, a complex regulating primary cilia 5 function

Highlight ( Page 2)

Bbs5-/- mice displayed hyperphagia, learning 7 deficits, glucose/insulin intolerance, and disrupted metabolic hormones, phenocopying 8 human BBS

Highlight ( Page 2)

unique immunophenotype in white adipose tissue with 9 increased proinflammatory macrophages and dysfunctional regulatory T cells, 10 suggesting a distinct mechanism for adiposity compared to typical obesity models

Highlight ( Page 2)

Hypothalamic transcriptomics 13 revealed dysregulated endocrine signaling pathways with functional analyses confirming 14 defects in insulin, leptin, and cholecystokinin (CCK) signalling, while preserving 15 glucagon-like peptide-1 receptor (GLP-1R) responsiveness. Notably, treatment with a 16 GLP-1R agonist effectively alleviated hyperphagia, body weight gain, improved glucose 17 tolerance, and circulating metabolic hormones in Bbs5-/- mice.